{
    "nct_id": "NCT06062810",
    "official_title": "Explore the Relationship Between Single Nucleotide Polymorphisms and Crizotinib Response and Toxicity in Patients With Non-Small Cell Lung Cancer",
    "inclusion_criteria": "1. Clinical diagnosis of Non-Small Cell Lung Cancer (NSCLC)\n2. Clinical lung tissue biopsy diagnosis of NSCLC\n3. Suitable for enough lung tissue biopsy of NSCLC\n4. Random and double blind\n5. Measurable disease\n6. Adequate organ functions\n7. Adequate performance status\n8. Age 22 years old and over\n9. Sign an informed consent form\n10. Receive blood-drawing\nHealthy volunteers allowed\nMust have minimum age of 22 Years\nMust have maximum age of 75 Years",
    "exclusion_criteria": "1. Pneumonectomy\n2. Treatment with other anti-cancer therapies and cannot be stopped currently\n3. Pregnancy\n4. Breast-feeding\n5. The patients with other serious intercurrent illness or infectious diseases\n6. Have more than one different kind of cancer at the same time\n7. Serious Allergy to Drugs\n8. Serious Bleed Tendency\n9. Serious Risks or Serious Adverse Events of the drug product\n10. The prohibition of drug products\n11. Have no therapeutic effects\n12. Follow up to the most current label",
    "miscellaneous_criteria": "* Select 600 Non-Small Cell Lung Cancer Patients who are suitable for lung tissue biopsy\n* Dosage Duration at least 90 days\n* The usual approach group - Recruit 300 double blind random group separated NSCLC patients currently used the Combined Chemotherapy High Dose on XALKORI - crizotinib capsule, film coated after lung tissue biopsy, like as the usual approach group.\n* The study approach group - Recruit 300 double blind random group separated NSCLC patients currently used the Combined Chemotherapy Low Dose on XALKORI - crizotinib capsule, film coated after lung tissue biopsy, like as the study approach group."
}